OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Nuclear Medicine is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Practicing Medicine in Wartime Ukraine	212
Prostate-Specific Membrane Antigen–Targeted Imaging and Its Correlation with HOXB13 Expression	155
Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States	124
CCK₂Receptor Ligand [⁶⁸Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [⁶⁸Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer	124
Positron Range Correction Helps Enhance the Image Quality of Cardiac⁸²Rb PET/CT	118
One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study	113
Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer	110
Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions	109
Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities	101
⁶⁸Ga-PSMA PET/CT–Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines	95
Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of^99mTc and¹⁸⁸Re Theranostic Agents for Prostate Cancer	93
Interspecies Variability in Biodistribution and PET Imaging Performance of [¹⁸F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer	90
State of the Art: Precision Surgery Guided by Intraoperative Molecular Imaging	84
Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [¹⁸F]PSMA-1007 PET/CT	84
Ambient Light Resistant Shortwave Infrared Fluorescence Imaging for Preclinical Tumor Delineation via the pH Low-Insertion Peptide Conjugated to Indocyanine Green	83
Clinical Experience with [²²⁵Ac]Ac-PSMA Treatment in Patients with [¹⁷⁷Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer	79
Serial [¹⁸F]AlF-NOTA-FAPI PET/CT and CT Angiography in Type B Aortic Dissection Before and After Thoracic Endovascular Aortic Repair	76
Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls	71
Impact of Single-Time-Point Estimates of¹⁷⁷Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles	71
Combined PARP1-Targeted Nuclear Contrast and Reflectance Contrast Enhance Confocal Microscopic Detection of Basal Cell Carcinoma	71
[¹⁷⁷Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial	66
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study	64
Preclinical Evaluation of²²⁶Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy	64
Quantitative Deauville Scoring to Uncover Prognostic Information from ¹⁸F-FDG PET–Based Response Assessment: Data from the EuroNet-PHL-C1 Trial	59
MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals	58

Localized In Vivo Prodrug Activation Using Radionuclides	56
¹⁷⁷Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial	55
Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [¹⁵O]H₂O PET Imaging	54
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma	54
Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually)	53
2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 2	52
First-in-Human Study of [¹¹C]NCGG401 for Imaging Colony-Stimulating Factor 1 Receptors in the Brain	52
Challenges with¹⁷⁷Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice	51
¹⁶¹Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with¹⁷⁷Lu in Preclinical Models of Ovarian Cancer	50
Biodistribution, Safety Profile, and Radiation Dosimetry of [¹⁸F]SYN2, a PET Cardiac Perfusion Tracer, in Healthy Subjects	50
Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient Care	49
The Role of Molecular Imaging in Precision Oncology	48
Funding Reductions Threaten the Future of Medical Innovation	48
Preclinical Characterization of the Tau PET Tracer [¹⁸F]SNFT-1: Comparison of Tau PET Tracers	48
Reply to “Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals”	45
Early-Phase¹⁸F-Florbetapir and¹⁸F-Flutemetamol Images as Proxies of Brain Metabolism in a Memory Clinic Setting	45
¹⁸F-FDG PET in Myocardial Viability Assessment: A Practical and Time-Efficient Protocol	45
Single Chelator–Minibody Theranostic Agents for⁸⁹Zr PET Imaging and¹⁷⁷Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer	44
Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses	44
Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection	43
Nanoparticle Diagnostics and Theranostics in the Clinic	43
Deep Learning–Based Attenuation Correction Improves Diagnostic Accuracy of Cardiac SPECT	43
Imaging Inflammation Past, Present, and Future: Focus on Cardioimmunology	43
Reply LTE, Single time point tumour dosimetry assuming normal distribution of tumour kinetics	42
Precision Medicine Clinical Trials	42
α-Synuclein Seeding Amplification Assay: A Breakthrough in Diagnosing Parkinson Disease?	41
Dual-Tracer Imaging on a Long–Axial-Field-of-View PET: A Proof-of-Principle Study with [¹⁸F]FGln and [¹⁸F]FDG	41
High-Resolution Silicon Photomultiplier Time-of-Flight Dedicated Head PET System for Clinical Brain Studies	41
Clinical Decision Support for Axillary Lymph Node Staging in Newly Diagnosed Breast Cancer Patients Based on¹⁸F-FDG PET/MRI and Machine Learning	41
Diuresis During¹⁸F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial	40
Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem	40
¹⁷⁷Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?	40
Molecular Imaging Leadership in Academia and Industry	40
Dual-Time-Point Posttherapy¹⁷⁷Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients’ Outcome	39
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)	39
An Analysis of the Distribution of PSMA PET/CT–Positive Lymph Nodes and Their Coverage by Different Elective Nodal Radiation Volumes in Postoperative Prostate Cancer Patients	38
Submillimeter-Resolution PET for High-Sensitivity Mouse Brain Imaging	38
Addition of Peptide Receptor Radiotherapy to Immune Checkpoint Inhibition Therapy Improves Outcomes in Neuroendocrine Tumors	37
Synthesis and Preclinical Evaluation of ¹⁷⁷Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer	37
Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the⁶⁸Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer	37
Development and Preclinical Evaluation of [⁶⁴Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics	37
Intrapatient 16α-[¹⁸F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor–Positive Metastatic Breast	37
Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is It an Either/Or Question?	37
Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [⁶⁸Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer	37
Molecular Imaging, Radiochemistry, and Environmental Pollutants	36
Feasibility of¹⁷⁷Lu-PSMA Administration as Outpatient Procedure for Prostate Cancer	36
Tumor Dose–Response Relationship of [¹³¹I]MIBG Therapy in Patients with Neural Crest Tumors by Means of [¹²⁴I]MIBG PET	36
Evaluating Bone Healing with [¹⁸F]NaF PET/CT During Bone Segment Transport in Femoral Fracture Treatment	35
The Translation of Dosimetry into Clinical Practice: What It Takes to Make Dosimetry a Mandatory Part of Clinical Practice	35
Progression or Response: New Liver Lesions in a Patient with Responding Hodgkin Lymphoma	35

An External, Independent Validation of anO-(2-[¹⁸F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma	35
Is It Too Soon to Know When It’s LATE?	34
Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET	33
Comparison of ¹¹C-Pittsburgh Compound B and ¹⁸F-Flutemetamol White Matter Binding in PET	33
Pretargeted Radioimmunotherapy of Ovarian Cancer with²²⁵Ac and an Internalizing Antibody	33
ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner–Collimator Configurations for²²³Ra-Based Radiopharmaceutical Therapies	33
Outcome of Patients with PSMA PET/CT Screening Failure by VISION Criteria and Treated with ¹⁷⁷Lu-PSMA: A Multicenter Retrospective Analysis	33
Immuno-PET Detects Antibody–Drug Potency on Coadministration with Statins	33
The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy	32
First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using¹⁸F-labeled Active-Site Inhibited Factor VII (¹⁸F-ASIS): Potential as Companion	32
Comparison of Baseline⁶⁸Ga-FAPI and¹⁸F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibit	32
Safety and Efficacy of Radiosynoviorthesis: A Prospective Canadian Multicenter Study	31
Phase II Trial Assessing the Repeatability and Tumor Uptake of [⁶⁸Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma	31
Total-Body PET/CT Applications in Cardiovascular Diseases: A Perspective Document of the SNMMI Cardiovascular Council	31
¹⁷⁶Lu Radiation in Long–Axial-Field-of-View PET Scanners: A Nonissue for Patient Safety	31
Prospective Multicenter Evaluation of [¹¹C]Methionine PET/MRI Sensitivity Compared with MRI for Localizing Small Pituitary Neuroendocrine Tumor or Pituitary Adenoma in Cushing Disease	31
Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from ⁶⁸Ga-DOTATOC PET/CT in Well-Differentiated Neuroendocrine Tumors	30
Tau PET Imaging in Neurodegenerative Disorders	30
First-in-Human Evaluation of Site-Specifically Labeled⁸⁹Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer	30
CD38-Targeted⁸⁹Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care	30
⁶⁸Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study	29
Potential of¹⁸⁸Re as an Alternative to¹⁷⁷Lu and Dosimetric Consequences	29
MIRD Pamphlet No. 27: MIRDcell V3, a Revised Software Tool for Multicellular Dosimetry and Bioeffect Modeling	29
Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins	29
Automated Brain Tumor Detection and Segmentation for Treatment Response Assessment Using Amino Acid PET	29
Identification of (R)-[¹⁸F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development	29
Head-to-Head Comparison of⁶⁸Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Pr	29
Green Nuclear Medicine and Radiotheranostics	29
Functional Imaging of Chemobrain: Usefulness of Nuclear Medicine in the Fog Coming After Cancer	29
How Many Theranostics Centers Will We Need in the United States?	29
First Safety and Efficacy Data with the Radiohybrid¹⁷⁷Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer	29
The Imperative for Comparative Studies in Nuclear Medicine: Elevating¹⁷⁷Lu-PSMA-617 in the Treatment Paradigm for mCRPC	29
Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with¹⁷⁷Lu-DOTATATE in Neuroendocrine Tumor Patients	28
Arrhythmias in Nongranulomatous Myocarditis: Is There a Role for PET?	28
Efficacy, Safety, Blood Kinetics, and ²¹³Bi Distribution Studies of [²²⁵Ac]Ac-SibuDAB in Prostate Cancer Patients	28
Total Body PET – Will it Change Science and Practice?	28
Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with ¹⁷⁷Lu-PSMA Therapy: A Multicenter Retrospective Analysis	28
CD70-Targeted [¹⁸F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study	28
Preirradiation of Spheroids with ²²⁵Ac-Trastuzumab Improves Penetration of ²²⁵Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails	28
Tau PET Visual Reads: Research and Clinical Applications and Future Directions	28
Posterior Cingulate Involvement Does Not Argue Against LATE	28
Quantitative [⁸⁹Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI	28
Molecular Imaging in Breast Cancer	28
Diagnostic Potential of Supplemental Static and Dynamic⁶⁸Ga-FAPI-46 PET for Primary¹⁸F-FDG–Negative Pulmonary Lesions	28
MHC-I–Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy	28
Histologic Ex Vivo Validation of the [¹⁸F]SITATE Somatostatin Receptor PET Tracer	28
Quantitative Brain Amyloid PET	27
¹⁶¹Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas	27
[⁶⁸Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis	27
The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective	26
High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections	26
Differential Effects of Tau Stage, Lewy Body Pathology, and Substantia Nigra Degeneration on¹⁸F-FDG PET Patterns in Clinical Alzheimer Disease	26
The Rise of Molecular Image–Guided Robotic Surgery	26
MIRD Pamphlet No. 29: MIRDy90—A⁹⁰Y Research Microsphere Dosimetry Tool	26
Not All Gatekeepers Are Theranostics	26
First-in-Human Study of¹⁸F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding	26
Can Internal Carotid Arteries Be Used for Noninvasive Quantification of Brain PET Studies?	26
Amino Acid PET in Neurooncology	26
High-Resolution Positronium Lifetime Tomography at Clinical Activity Levels on the PennPET Explorer	26
Modeling early radiation DNA damage occurring during [¹⁷⁷Lu]Lu-DOTA-[Tyr³]octreotate radionuclide therapy	26
Distinguishing Progression from Pseudoprogression in Glioblastoma Using¹⁸F-Fluciclovine PET	25
Detecting CXCR4 Expression in Meningioma on⁶⁸Ga-Pentixafor PET/MRI	25
Increased Metabolic Activity of the Thymus and Lymph Nodes in Pediatric Oncology Patients After Coronavirus Disease 2019 Vaccination	25
¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior²²³Ra (RALU Study)	25
A Pilot Study of⁶⁸Ga-PSMA11 and⁶⁸Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High-Intensity Focused Ultrasound Therapy	25
⁶⁴Cu-DOTA Enables Late PET Imaging and Leak Detection in the Cerebrospinal Fluid Space	25
Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET—An International Multicenter Retrospective Study	25
Histology-Based Radiomics for [¹⁸F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer	25
[¹⁸F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non–Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy	25
Detection of Early Esophageal Neoplastic Barrett Lesions with Quantified Fluorescence Molecular Endoscopy Using Cetuximab-800CW	24
FAPI PET/CT Immune-Fibrosis Imaging for New Insights into Rheumatologic Disorders	24
China’s Innovations in Nuclear Medicine: Global Insights into Clinical Advancements and Impact	24
Navigating Radiation Safety After Radiopharmaceutical Therapies: Proposed Workflow and Essential Guidelines for Nonspecialists	24
Recent Evidence on Cardiac^99mTc-DPD Uptake After Therapy with Tafamidis May Reveal the Road to an Ultra-Early Diagnosis in Patients with ATTR Amyloidosis	24
Redifferentiation of a RET-Fusion, Radioiodine-Refractory, Differentiated Thyroid Cancer with Selpercatinib: Flip-Flop Between [¹⁸F]FDG PET/CT and¹³¹I Posttreatment Scanning	24
^99mTc-MIP-1404 SPECT/CT Companion Diagnostic for¹⁷⁷Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer	24
Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of Immunotherapy	24
High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PET	23
Design, Preclinical Evaluation, and Clinical Translation of⁶⁸Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma	23
Evaluating Radiotheranostic Targets for Endometrial Cancer	23

Dosimetry of [¹⁷⁷Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial	23
Advancing Nuclear Medicine at the Multiomics Intersection	23
Stakeholders of Theranostics	23
Theranostics in Perspective: White Paper	23
Noninvasive Diagnostic Method to Objectively Measure Olfaction and Diagnose Smell Disorders by a Molecularly Targeted Fluorescence Imaging Agent	23
Future Directions in Molecular Imaging of Neurodegenerative Disorders	23
The Will Rogers Phenomenon and PSMA PET/CT	23
Association of Free-to-Total PSA Ratio and¹⁸F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Si	23
A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides	23
Total-Body ¹⁸F-FDG PET/CT in Autoimmune Inflammatory Arthritis at Ultra-Low Dose: Initial Observations	23
Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy	23
Preclinical Evaluation of Gastrin-Releasing Peptide Receptor Antagonists Labeled with¹⁶¹Tb and¹⁷⁷Lu: A Comparative Study	22
Delayed Imaging Improves Lesion Detectability in [^99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer	22
Safety and Survival Outcomes of¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior²²³Ra treatment: The RA	22
Redefining Nuclear Medicine: “Biodistribution” Should Be the Core Concept	22
Perspective on Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery	22
[⁶⁸Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria	22
Utility of⁶⁴Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on⁶⁸Ga-PSMA-11 PET/CT	22
Safety, Dosimetry, and Feasibility of [⁶⁸Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer	22
Tracking Innate Immune Activation in a Mouse Model of Parkinson’s Disease Using TREM1 and TSPO PET Tracers	22
Imaging Efficacy of [¹⁸F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath—A Phase 3, Prospective Multicenter Study	21
Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from Analysis of The Cancer Genome Atlas	21
Automated Total-Body Perfusion Imaging with ¹⁵O-Water PET Using Basis Functions and Organ-Specific Model Selection	21
Prostate-Specific Membrane Antigen PET/CT–Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer	21
The DETECT Trial: Are We on the Verge of Precision Surgery in Primary Prostate Cancer?	21
MIRD Pamphlet No. 31: MIRDcell V4—Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy	21
¹⁸F-AlF-NOTA-Octreotide Outperforms⁶⁸Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study	21
The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for¹⁶¹Tb Compared with¹⁷⁷Lu with a Higher Dose Response for [¹⁶	21
Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy	21
Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy	21
Theranostic Digital Twins: An Indispensable Prerequisite for Personalized Cancer Care	21
Multicenter Evaluation of Frequency and Impact of Activity Infiltration in PET Imaging, Including Microscale Modeling of Skin-Absorbed Dose	21
¹⁸F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy	21
⁶⁸Ga-FAPI-04 PET/CT in Non–Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression	21
Advancing Tomorrow’s Cancer Medicines	21
Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on ¹⁸F-rhPSMA-7.3 PET/CT in patients with prostate cancer	20
⁶¹Cu-Labeled Radiotracers: Alternative or Choice?	20
First-in-Human Study of¹⁸F-Labeled PET Tracer for Glutamate AMPA Receptor [¹⁸F]K-40: A Derivative of [¹¹C]K-2	20
Effect of Acute Hypoxia Exposure on the Availability of A₁Adenosine Receptors and Perfusion in the Human Brain	20
Translational Potential of Fluorescent PARP1 Inhibitor as a Molecular Contrast Agent for Diagnosis of Basal Cell Carcinoma	20
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE	20
Antihormonal-Treatment Status Affects⁶⁸Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer	20
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)	20
SPECT Deserves RESPECT: The Potential of SPECT/CT to Optimize Patient Outcomes with Theranostics Therapy	20
[¹⁸F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lu	20
Reply: Dosimetry in Radiopharmaceutical Therapy	20
A New Dawn	20
Evaluation of Mitochondrial Complex 1 Density with [¹⁸F]BCPP-EF in a Murine Model and Individuals with Friedreich Ataxia	20
¹⁸F-DOPA PET/CT at the Forefront of Initial or Presurgical Evaluation of Small-Intestine Neuroendocrine Tumors	20
SV2A PET Imaging Is a Noninvasive Marker for the Detection of Spinal Damage in Experimental Models of Spinal Cord Injury	20
Toward a Better Understanding of Immune Checkpoint Inhibitor Radiolabeled PET Imaging Studies	19
Differences in Fibroinflammatory Activity Shown on⁶⁸Ga-FAPI-04 and¹⁸F-FDG PET/CT in the Two Subtypes of IgG4-Related Disease	19
Epidermal growth factor receptor targeted fluorescence molecular imaging for postoperative lymph node assessment in patients with oral cancer	19
Preclinical Investigation of [²¹²Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model	19
Nuclear Cardiology Surrogate Biomarkers in Clinical Trials	19
Virtual Biopsy: Just an AI Software or a Medical Procedure?	19
Recent Advances in Radiotracers Targeting Novel Cancer-Specific Biomarkers in China: A Brief Overview	19
Changes in Management After ¹⁸F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes	19
PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy	19
[¹¹C]Carfentanil PET Whole-Body Imaging of μ-Opioid Receptors: A First in-Human Study	19
Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer	19
Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis	19
Quantitative Total-Body Imaging of Blood Flow with High-Temporal-Resolution Early Dynamic¹⁸F-FDG PET Kinetic Modeling	19
ChatGPT: Can You Prepare My Patients for [¹⁸F]FDG PET/CT and Explain My Reports?	19
From Scientist to Analyst to Strategist	18
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up	18
Myocardial External Efficiency in Asymptomatic Severe Primary Mitral Regurgitation Using¹¹C-Acetate PET	18
The Future of Nuclear Medicine in the United States	18
Molecular Imaging of Systemic and Cardiac Amyloidosis: Recent Advances and Focus on the Future	18
Noninvasive Assessment of Acute Graft-Versus-Host Disease of the Gastrointestinal Tract After Allogeneic Hemopoietic Stem Cell Transplantation Using¹⁸F-FDG PET	18
Total-Body Parametric Imaging Using Relative Patlak Plot	18
Performance Evaluation of the uMI Panorama PET/CT System in Accordance with the National Electrical Manufacturers Association NU 2-2018 Standard	18
Targeted α-Emitter Therapy with ²¹²Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial	18
Advancing Clinical Trial Innovation in Pancreatic Cancer	18
Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy	18
Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of¹⁸F-FDG PET/CT and Conventional CT Imaging	18
2024 SNMMI Highlights Lecture: General Clinical Specialties	18
Immunohistochemical FAP Expression Reflects⁶⁸Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma	18
Advancing Nuclear Medicine in Australia over 3 Decades	18
Enhancing ²²³Ra Treatment Efficacy by Anti-β1 Integrin Targeting	18
Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice	18
Whole-Body PET Imaging in Humans Shows That¹¹C-PS13 Is Selective for Cyclooxygenase-1 and Can Measure the In Vivo Potency of Nonsteroidal Antiinflammatory Drugs	18
Evidence-Based Clinical Protocols to Monitor Efficacy of [¹⁷⁷Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data	17
Validation of the ΔSUV_maxfor Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial	17
Imaging of the Aging Human Brain	17
Exploring Vessel Wall Biology In Vivo by Ultrasensitive Total-Body PET	17
Optimized Whole-Body PET MRI Sequence Workflow in Pediatric Hodgkin Lymphoma Patients	17
[¹⁷⁷Lu]Lu-PSMA Therapy as an Individual Treatment Approach for Patients with High-Grade Glioma: Dosimetry Results and Critical Statement	17
Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer	17
Interrogating Glioma-Associated Microglia and Macrophage Dynamics Under CSF-1R Therapy with Multitracer In Vivo PET/MRI	17
Development of Fluorinated NP-59: A Revival of Cholesterol Use Imaging with PET	17
Image-Derived Blood Normalization of Antibody-Based TREM2 PET in Mouse Models of Amyloidosis and Myocardial Infarction	17
Dynamic Tumor-Specific MHC-II Immuno-PET Predicts Checkpoint Inhibitor Immunotherapy Efficacy in Melanoma	17
Is Routine Dosimetry Really Happening?	17
Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition	17